First Tracks Biotherapeutics Reports Positive Phase 1b Data
First Tracks Biotherapeutics shares positive topline data from its Phase 1b cohort of ANB033 in Celiac Disease, signaling growth potential in the pharmaceutical sector.
Gulf Resources to Resume Production at Bromine Factories
Gulf Resources, Inc. receives approval to restart production at two bromine factories, signaling a recovery for the company and the chemicals industry.
Quaint Oak Bancorp declares quarterly cash dividend
Quaint Oak Bancorp, Inc. announces a quarterly cash dividend of $0.04 per share, payable on November 9, 2026, to shareholders of record.
Edesa Biotech Receives FDA Clearance for EB06 Study
Edesa Biotech, Inc. has received FDA clearance for its Phase 2 clinical study of EB06 in vitiligo, expanding patient recruitment into the U.S.
ASP Isotopes Announces Joint Venture with Necsa for Uranium Production
ASP Isotopes Inc. partners with Necsa to develop a facility for High-Assay Low-Enriched Uranium production, marking a strategic move in the nuclear sector.
Allstate reports estimated catastrophe losses for September 2026
Allstate Corp discloses estimated catastrophe losses for September 2026, impacting its financial outlook and the broader fire, marine, and casualty insurance sector.
Krystal Biotech Reports Positive Data for KB113 in Gorlin Syndrome
Krystal Biotech reveals encouraging clinical data for KB113, an immunotherapy for basal cell carcinoma in Gorlin syndrome patients, at PeDRA conference.
Rezolute completes enrollment in Phase 3 upLIFT study
Rezolute, Inc. announces the completion of patient enrollment in its Phase 3 upLIFT study for treating tumor hyperinsulinism with ersodetug.
i-80 Gold Corp. Updates Corporate Presentation for Investors
i-80 Gold Corp. has released an updated corporate presentation, reflecting its ongoing developments and commitment to transparency in the gold and silver ores industry.
ImmunityBio Expands ANKTIVA Approval for Bladder Cancer Treatment
ImmunityBio announces FDA approval for ANKTIVA to treat BCG-unresponsive bladder cancer, expanding treatment options for patients with papillary tumors.
Mattel amends CEO Roger Lynch's employment agreement
Mattel Inc. amends CEO Roger Lynch's employment agreement, enhancing his compensation and severance terms, signaling a focus on leadership stability.
STRATTEC Security Corp Announces Governance Changes
STRATTEC Security Corp's recent SEC filing reveals important governance and financial updates, impacting the motor vehicle parts industry.
Parks! America appoints new transfer agent Clear Trust
Parks! America, Inc. has appointed Clear Trust, LLC as its new transfer agent, aiming to enhance shareholder services and operational management.
SLM Student Loan Trust 2004-5 Issues Remarketing Memorandum
SLM Student Loan Trust 2004-5 has issued a preliminary remarketing memorandum for its Class A-6 Reset Rate Notes, signaling ongoing activity in the asset-backed securities market.
Braemar Hotels releases preliminary financial results
Braemar Hotels & Resorts Inc. shares preliminary financial results, indicating potential changes in revenue and performance metrics for its property portfolio.
ProText Mobility Files 8-K to Enhance Transparency and Shareholder Alignment
ProText Mobility, Inc. voluntarily files an 8-K to boost transparency and prepare for potential uplisting, reaffirming management's commitment to shareholders.
Steele Creek Capital Corp Announces Liquidation Approval
Steele Creek Capital Corp has received stockholder approval for its liquidation and dissolution plan, signaling a major shift for the company.
SLM Student Loan Trust 2004-10 Reports Remarketing Activity
SLM Student Loan Trust 2004-10 details remarketing of Class A-7A, A-7B, and A-8 Reset Rate Notes in recent SEC filing.
BMW Vehicle Lease Trust 2026-2 files 8-K on legal counsel
BMW Vehicle Lease Trust 2026-2 files an 8-K report detailing legal counsel retained for its registration statement, highlighting compliance in asset-backed securities.
Oncolytics Biotech expects final PanCAN grant payment
Oncolytics Biotech Inc. anticipates receiving the final grant payment from PanCAN as it concludes enrollment in the GOBLET study, with more clinical data to follow.